-
公开(公告)号：US20210178135A1
公开(公告)日：2021-06-17
申请号：US17054621
申请日：2019-05-10
发明人： Herbert Brinkman , John Koleng , Aron Aizenstat , Andrew Sklawer , Tatsuro Nagao , Masayoshi Takaoka
摘要： An applicator and applicator system are provided for a topically or transdermally applying a pharmaceutical preparation or formulation. The applicator and applicator system can reduce drip during use, provide efficient transfer of a dose of the pharmaceutical preparation or formulation from the applicator to the skin of a patient, and can be used hands-free, which can reduce, prevent or eliminate cross-contamination to other areas, including undesired application to other parts of the skin or to other individuals. The applicator and applicator system include a therapeutic surface which can receive a single dose of the pharmaceutical preparation and can be manipulated by the user to transfer and apply the pharmaceutical preparation on a body surface.
-
公开(公告)号：US09572785B2
公开(公告)日：2017-02-21
申请号：US14468183
申请日：2014-08-25
IPC分类号： A61K31/4418 , A61K31/195 , C07D213/64 , C07C229/00
CPC分类号： A61K31/195
摘要： Described herein is the DP2 antagonist [2′-(3-benzyl-1-ethyl-ureidomethyl)-6-methoxy-4′-trifluoromethyl-biphenyl-3-yl]-acetic acid, or a pharmaceutically acceptable salt thereof. Also described are methods of preparing the DP2 antagonist, or a pharmaceutically acceptable salt thereof. Also described herein are pharmaceutical compositions suitable for administration to a mammal that include the DP2 antagonist, or a pharmaceutically acceptable salt thereof, and methods of using such pharmaceutical compositions for treating respiratory diseases or conditions, allergic diseases or conditions, inflammatory diseases or conditions, as well as other prostaglandin D2-dependent or prostaglandin D2-mediated diseases or conditions.
摘要翻译： 本文描述的是DP2拮抗剂[2' - （3-苄基-1-乙基 - 脲基甲基）-6-甲氧基-4'-三氟甲基 - 联苯-3-基] - 乙酸或其药学上可接受的盐。 还描述了制备DP2拮抗剂或其药学上可接受的盐的方法。 本文还描述了适用于给予哺乳动物包括DP2拮抗剂或其药学上可接受的盐的药物组合物，以及使用这些药物组合物治疗呼吸系统疾病或病症，过敏性疾病或病症，炎性疾病或病症的方法，如 以及其他前列腺素D2依赖性或前列腺素D2介导的疾病或病症。
-
公开(公告)号：US20210171460A1
公开(公告)日：2021-06-10
申请号：US17105376
申请日：2020-11-25
IPC分类号： C07D207/12 , A61K9/00 , C07C59/147
摘要： A cocrystal containing the 1′R-diastereomer and the 1'S-diastereomer of sofpironium bromide at a ratio of 1:3 (Form CO), a crystal mixture (for example, Form B) containing Form CO and a crystalline form of the 1′R-diastereomer (Form MN), and a method for preparing sofpironium bromide, which is suitable for manufacture of the crystal mixture are provided. Form CO and a crystalline form of sofpironium bromide containing Form CO (for example, Form B) have superior stability without hygroscopic property, and accordingly they can be preferably used as a raw material of medicaments.
-
公开(公告)号：USD998143S1
公开(公告)日：2023-09-05
申请号：US29669710
申请日：2018-11-09
设计人： Tatsuro Nagao , Masayoshi Takaoka
摘要： FIG. 1 is a perspective view of an Applicator for Pharmaceutical Preparation embodying our design.
FIG. 2 is a front elevational view thereof.
FIG. 3 is a top plan view thereof.
FIG. 4 is a bottom plan view thereof.
FIG. 5 is a side elevational view thereof, showing the Applicator for Pharmaceutical Preparation rotated 90° from the elevational view in FIG. 2.
FIG. 6 is a cross-sectional view thereof, taken in the direction of line 6-6 in FIG. 2.
The broken lines depict portions of the Applicator for Pharmaceutical Preparations that form no part of the claimed design.-
5.发明申请公开(公告)号：US20190047933A1
公开(公告)日：2019-02-14
申请号：US16084905
申请日：2017-03-15
申请人： Ulrich ABEL , József RÉPÁSI , András SZABÓ , Cserépi Stefánia SZÜCSNÉ , Ádám BOR , Brickell Biotech, Inc.
发明人： Ulrich Abel , József Répási , András Szabó , Cserépi Stefánia Szücsné , Ádám Bor
IPC分类号： C07C51/353 , C07C51/43 , C07C51/09 , C07C29/147 , C07C45/30 , C07C67/307 , C07C67/343
摘要： This invention relates to a novel method for the synthesis of (2E,4E,6Z,8E)-8-(3,4-dihydronaphthalen-1(2H)-ylidene)-3,7-dimethylocta-2,4,6-trienoic acid. In particular, the invention relates to several improvements in several individual steps of the multi-step synthesis scheme
-
公开(公告)号：US20150259283A1
公开(公告)日：2015-09-17
申请号：US14285488
申请日：2014-05-22
发明人： John J. Koleng , David Angulo
IPC分类号： C07D207/12 , A61K33/06 , A61K31/40
CPC分类号： C07D207/12 , A61K9/0014 , A61K9/08 , A61K31/40 , A61K33/06 , A61K47/10 , A61K47/24 , A61K47/38 , A61K2300/00
摘要： Topical formulations comprising soft glycopyrrolates are useful for treating excessive sweating conditions in subjects, such as humans suffering from hyperhidrosis. Preferably, at least one soft anticholinergic agent is provided in an effective amount or concentration in an anhydrous formulation that can inhibit excessive perspiration resulting from a condition such as hyperhidrosis.
摘要翻译： 包含软糖基吡咯烷酸盐的局部制剂可用于治疗受试者（例如患有多汗症的人）中的过度出汗状况。 优选地，在无水制剂中以有效量或浓度提供至少一种软抗胆碱剂，其可以抑制由多汗症等病症引起的过量出汗。
-
公开(公告)号：US20160136119A1
公开(公告)日：2016-05-19
申请号：US14468183
申请日：2014-08-25
IPC分类号： A61K31/195
CPC分类号： A61K31/195
摘要： Described herein is the DP2 antagonist [2′-(3-benzyl-1-ethyl-ureidomethyl)-6-methoxy-4′-trifluoromethyl-biphenyl-3-yl]-acetic acid, or a pharmaceutically acceptable salt thereof. Also described are methods of preparing the DP2 antagonist, or a pharmaceutically acceptable salt thereof. Also described herein are pharmaceutical compositions suitable for administration to a mammal that include the DP2 antagonist, or a pharmaceutically acceptable salt thereof, and methods of using such pharmaceutical compositions for treating respiratory diseases or conditions, allergic diseases or conditions, inflammatory diseases or conditions, as well as other prostaglandin D2-dependent or prostaglandin D2-mediated diseases or conditions.
摘要翻译： 本文描述了DP2拮抗剂[2' - （3-苄基-1-乙基 - 脲基甲基）-6-甲氧基-4'-三氟甲基 - 联苯-3-基] - 乙酸或其药学上可接受的盐。 还描述了制备DP2拮抗剂或其药学上可接受的盐的方法。 本文还描述了适用于给予哺乳动物包括DP2拮抗剂或其药学上可接受的盐的药物组合物，以及使用这些药物组合物治疗呼吸系统疾病或病症，过敏性疾病或病症，炎性疾病或病症的方法，如 以及其他前列腺素D2依赖性或前列腺素D2介导的疾病或病症。
-
公开(公告)号：US20210395197A1
公开(公告)日：2021-12-23
申请号：US17364445
申请日：2021-06-30
IPC分类号： C07D207/12 , A61K9/00 , C07C59/147
摘要： A cocrystal containing the 1′R-diastereomer and the 1′S-diastereomer of sofpironium bromide at a ratio of 1:3 (Form CO), a crystal mixture (for example, Form B) containing Form CO and a crystalline form of the 1′R-diastereomer (Form MN), and a method for preparing sofpironium bromide, which is suitable for manufacture of the crystal mixture are provided. Form CO and a crystalline form of sofpironium bromide containing Form CO (for example, Form B) have superior stability without hygroscopic property, and accordingly they can be preferably used as a raw material of medicaments.
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.016 秒)
